ZA9010392B - Method for the modification of the expression characteristics of an endogenous gene of given cell line or microorganism - Google Patents

Method for the modification of the expression characteristics of an endogenous gene of given cell line or microorganism

Info

Publication number
ZA9010392B
ZA9010392B ZA9010392A ZA9010392A ZA9010392B ZA 9010392 B ZA9010392 B ZA 9010392B ZA 9010392 A ZA9010392 A ZA 9010392A ZA 9010392 A ZA9010392 A ZA 9010392A ZA 9010392 B ZA9010392 B ZA 9010392B
Authority
ZA
South Africa
Prior art keywords
microorganism
modification
cell line
endogenous gene
given cell
Prior art date
Application number
ZA9010392A
Other languages
English (en)
Inventor
Scott C Chappel
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23806064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA9010392(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of ZA9010392B publication Critical patent/ZA9010392B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
ZA9010392A 1989-12-22 1990-12-27 Method for the modification of the expression characteristics of an endogenous gene of given cell line or microorganism ZA9010392B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45478389A 1989-12-22 1989-12-22

Publications (1)

Publication Number Publication Date
ZA9010392B true ZA9010392B (en) 1992-01-29

Family

ID=23806064

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9010392A ZA9010392B (en) 1989-12-22 1990-12-27 Method for the modification of the expression characteristics of an endogenous gene of given cell line or microorganism

Country Status (26)

Country Link
EP (5) EP0505500B1 (fr)
JP (3) JP3501286B2 (fr)
KR (1) KR0176693B1 (fr)
AR (1) AR245776A1 (fr)
AT (2) ATE264916T1 (fr)
AU (1) AU645294B2 (fr)
BG (1) BG60624B1 (fr)
BR (1) BR9007937A (fr)
CA (1) CA2071989C (fr)
DE (3) DE69031172T2 (fr)
DK (2) DK0779362T4 (fr)
ES (2) ES2151463T5 (fr)
FI (1) FI107391B (fr)
GR (1) GR3025057T3 (fr)
HK (2) HK1000547A1 (fr)
HU (1) HU217212B (fr)
IL (4) IL116046A (fr)
LT (1) LT3998B (fr)
LV (1) LV10655B (fr)
NO (1) NO311896B1 (fr)
OA (1) OA09594A (fr)
RO (1) RO109864B1 (fr)
RU (1) RU2128227C1 (fr)
UA (1) UA42675C2 (fr)
WO (1) WO1991009955A1 (fr)
ZA (1) ZA9010392B (fr)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
WO1991006666A1 (fr) * 1989-11-06 1991-05-16 Cell Genesys, Inc. Production de proteines par recombinaison homologue
US5643753A (en) 1990-04-18 1997-07-01 Connaught Laboratories Limited Use of autologous promoters to express gene products in bordetella
GB9008746D0 (en) * 1990-04-18 1990-06-13 Connaught Lab The use of autologous promoters to express gene products in bordetella
SG93780A1 (en) * 1991-05-06 2003-01-21 Cell Genesys Inc Gene manipulation and expression using genomic elements
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5733761A (en) * 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
WO1993023553A1 (fr) * 1992-05-19 1993-11-25 Exemplar Corporation Procede de production d'organismes transgeniques par liaison in vivo de regions codantes et de regulation
AU4401993A (en) * 1992-06-04 1993-12-30 Exemplar Corporation Insertion of heterologous dna outside of known chromosomal genes
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
DK153992D0 (da) * 1992-12-22 1992-12-22 Novo Nordisk As Metode
US5733753A (en) * 1992-12-22 1998-03-31 Novo Nordisk A/S Amplification of genomic DNA by site specific integration of a selectable marker construct
CZ289308B6 (cs) 1993-12-23 2001-12-12 Merck & Co., Inc. Homologní rekombinantní expresní vektor pro expresi rekombinantních genů a způsob exprese rekombinantních genů
AU738395B2 (en) * 1994-05-13 2001-09-20 Transkaryotic Therapies, Inc. DNA construct for effecting homologous recombination and uses thereof
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6124439A (en) * 1994-08-17 2000-09-26 The Rockefeller University OB polypeptide antibodies and method of making
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
US6737513B1 (en) 1996-06-07 2004-05-18 Icos Corporation Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US7084252B1 (en) 1996-01-16 2006-08-01 The Rockefeller University DB, the receptor for leptin
US7148004B1 (en) 1997-01-16 2006-12-12 The Rockefeller University Oligonucleotides of the OB-R isoforms and methods of diagnosing body weight
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US7619079B2 (en) 1996-02-14 2009-11-17 The Rockefeller University Db, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof
SG94355A1 (en) 1996-10-01 2003-02-18 Geron Corp Human telomerase catalytic subunit
US5925544A (en) * 1996-11-18 1999-07-20 Novo Nordisk A/S Method of homologous recombination followed by in vivo selection of DNA amplification
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US5888809A (en) * 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
KR100641969B1 (ko) 1997-07-23 2006-11-06 로셰 디아그노스틱스 게엠베하 내인성 유전자 활성화에 의한 에리트로포이에틴의제조방법
ATE341625T1 (de) * 1997-07-23 2006-10-15 Roche Diagnostics Gmbh Herstellung von erythropoietin durch endogene genaktivierung mit viralen promotoren
US6548296B1 (en) 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
US6897066B1 (en) * 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
US5932465A (en) * 1997-10-16 1999-08-03 Icos Corporation Phosphodiesterase 8A
AU757930B2 (en) * 1997-12-01 2003-03-13 Roche Diagnostics Gmbh Optimization of cells for endogenous gene activation
WO1999042596A2 (fr) 1998-02-23 1999-08-26 Icos Corporation Phosphodiesterase 10
US6479256B1 (en) 1998-03-04 2002-11-12 Icos Corporation Lectomedin materials and methods
US6200951B1 (en) 1998-03-12 2001-03-13 Icos Corporation Chitinase chitin-binding fragments
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6541623B1 (en) 1998-04-03 2003-04-01 Hyseq, Inc. Interleukin—1 receptor antagonist and uses thereof
US6426191B1 (en) 1998-04-03 2002-07-30 Hyseq, Inc. Assays involving an IL-1 receptor antagonist
US6294655B1 (en) 1998-04-03 2001-09-25 Hyseq, Inc. Anti-interleukin-1 receptor antagonist antibodies and uses thereof
US6071691A (en) * 1998-04-27 2000-06-06 Oregon Health Science University Materials and methods for modulating differentiation
US6492138B1 (en) 1998-05-21 2002-12-10 Amgen Canada Inc. Polynucleotides encoding a novel SHC-binding protein
AU4213999A (en) * 1998-05-27 1999-12-13 Novo Nordisk Biotech, Inc. Methods for producing a polypeptide by modifying the copy number of a gene
US6447771B1 (en) 1999-03-19 2002-09-10 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
MXPA01000481A (es) 1998-07-16 2002-11-29 Hyseq Inc Metodos y materiales relacionados con polipeptidos tipo cd39 novedosos.
US6476211B1 (en) 1998-07-16 2002-11-05 Hyseq, Inc. Methods and materials relating to CD39-like polypeptides
US6387645B1 (en) 1998-07-16 2002-05-14 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
US6773911B1 (en) 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
JP2002533693A (ja) 1998-12-23 2002-10-08 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー 苦味応答のインヒビター
US6899875B1 (en) 1999-01-29 2005-05-31 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6783959B1 (en) 1999-01-29 2004-08-31 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6350447B1 (en) 1999-01-29 2002-02-26 Hyseq, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6780977B1 (en) 1999-01-29 2004-08-24 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
EP1155131B1 (fr) * 1999-02-19 2008-07-23 ABT Holding Company Vector comprenant une trappe d'accepteur d'epissage et une trappe poly a et les cellules eucaryotes correspondantes
US6335013B1 (en) 1999-03-19 2002-01-01 Hyseq, Inc. Methods and materials relating to CD39-like polypeptides
WO2000058479A1 (fr) 1999-03-26 2000-10-05 Amgen Inc. Genes et polypeptides beta secretase
CN1370238A (zh) 1999-06-16 2002-09-18 艾科斯有限公司 人聚(adp－核酸)聚合酶2的物质和方法
US6632665B1 (en) 1999-08-09 2003-10-14 Wake Forest University Human gene encoding 3′-5′ exonuclease
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US6900043B1 (en) 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
US6344549B1 (en) 1999-10-14 2002-02-05 Icos Corporation ATR-2 cell cycle checkpoint
AU783082B2 (en) 1999-10-22 2005-09-22 Pharmacia & Upjohn Company Drosophila G protein coupled receptors, nucleic acids, and methods related to the same
US7314716B2 (en) 1999-11-19 2008-01-01 Mount Sinai School Of Medicine Gustducin γ subunit materials and methods
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
US6586390B1 (en) 2000-01-21 2003-07-01 Hyseq, Inc. Methods and materials relating to novel prothrombinase-like polypeptides and polynucleotides
US6465620B1 (en) 2000-01-21 2002-10-15 Hyseq, Inc. Methods and materials relating to novel von Willebrand/Thrombospondin-like polypeptides and polynucleotides
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
AU2001274894A1 (en) 2000-05-22 2001-12-03 Pharmacia And Upjohn Company Novel matrix metalloproteinases
PT2077279E (pt) 2000-06-28 2012-09-14 Amgen Inc Moléculas do receptor de linfopoietina estromal tímica e suas utilizações
EP1307551A2 (fr) 2000-07-05 2003-05-07 PHARMACIA & UPJOHN COMPANY Canaux ioniques humains
GB0018876D0 (en) 2000-08-01 2000-09-20 Applied Research Systems Method of producing polypeptides
US6787684B2 (en) 2000-10-16 2004-09-07 E. & J. Gallo Winery Lipoxygenase genes from Vitis vinifera
DE60144439D1 (de) 2000-12-20 2011-05-26 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
US7883856B2 (en) 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
US7803982B2 (en) 2001-04-20 2010-09-28 The Mount Sinai School Of Medicine Of New York University T1R3 transgenic animals, cells and related methods
ES2324525T3 (es) 2001-06-20 2009-08-10 Dainippon Sumitomo Pharma Co., Ltd. Metodo para promover transferencia de acidos nucleicos.
EP2327985B2 (fr) 2001-06-26 2019-08-21 Senomyx, Inc. Récepteurs du goût hétéro-oligomériques T1R et lignées cellulaires qui expriment ces récepteurs et utilisation associée pour l'identification des composants du goût
AU2002318229B2 (en) 2001-07-10 2008-03-13 Senomyx, Inc. Use of specific T2R taste receptors to identify compounds that block bitter taste
US7662924B2 (en) 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US7205398B2 (en) 2002-05-24 2007-04-17 Schering-Plough Animal Health Corporation Eta-1 gene and methods for use
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
BR0315155A (pt) 2002-10-08 2005-08-16 Ares Trading Sa Uso de citocina capaz de ligar il-18bp e de inibir a atividade de uma segunda citocina
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
WO2004064785A2 (fr) 2003-01-14 2004-08-05 Dana Farber Cancer Institute Sensibilisant d'une therapie de cancer
ES2625342T3 (es) 2003-06-27 2017-07-19 Monell Chemical Senses Center Receptores gustativos de la familia T1R del gato doméstico
SG153714A1 (en) 2003-08-06 2009-07-29 Senomyx Inc T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
CA2539440A1 (fr) 2003-09-29 2005-04-14 Warren Pharmaceuticals, Inc. Cytokines de protection des tissus pour le traitement et la prevention des septicemies et de la formation d'adhesions
EP1696034A4 (fr) * 2003-12-19 2006-12-27 Dainippon Sumitomo Pharma Co Methode de transfert d'acide nucleique
US7541158B2 (en) 2004-04-14 2009-06-02 Monell Chemical Senses Center Taste receptors of the T1R family from domestic dog
BRPI0508928B1 (pt) 2004-04-23 2015-10-06 Pah P & U Llc Processo de falicitação da infecção de uma célula de vertebrado por PRRSV e para medir a propensão de uma linhagem de células teste à referida infecção
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
JP2008511678A (ja) 2004-09-02 2008-04-17 イェール ユニバーシティ マイクロｒｎａによるオンコジーンの調節
WO2006066064A2 (fr) 2004-12-13 2006-06-22 Monell Chemical Senses Center Canal anionique sensible au ph et au voltage et son nouveau variant d'epissage intervenant dans la sensation gustative
WO2006072625A2 (fr) 2005-01-06 2006-07-13 Novo Nordisk A/S Procedes et traitements combines anti-kir
WO2006101629A2 (fr) 2005-02-17 2006-09-28 Vertex Pharmaceuticals Incorporated Variant d'epissage d'une sous-unite alpha de proteine type iii de canal sodique
CN101218256B (zh) 2005-03-23 2017-04-19 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
WO2007002528A1 (fr) 2005-06-23 2007-01-04 Yale University Micro-arn anti-vieillissement
WO2007031566A1 (fr) 2005-09-14 2007-03-22 Ares Trading S.A. Méthode de dosage quantitatif des poloxamères
US7972813B2 (en) 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
CN101605810B (zh) 2005-10-20 2013-07-17 塞诺米克斯公司 嵌合的人甜味-鲜味和鲜味-甜味受体
WO2007067564A2 (fr) 2005-12-08 2007-06-14 Amgen Inc. Cellules hotes ameliorees et procedes de culture
DE102006004008A1 (de) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
TWI425917B (zh) 2006-04-21 2014-02-11 Senomyx Inc 包含高度鮮味風味劑之可食用組合物及其製造方法
EA200971050A1 (ru) 2007-05-11 2010-06-30 Томас Джефферсон Юниверсити Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
EP2155225B1 (fr) 2007-05-11 2015-07-08 The Trustees of the University of Pennsylvania Procédés de traitement des ulcères de la peau
CL2008002053A1 (es) 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
AR067536A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
WO2009010107A1 (fr) 2007-07-19 2009-01-22 Hannelore Ehrenreich Utilisation d'activation ou de stimulation du récepteur de l'epo pour l'amélioration du score edss dans des patients présentant une sclérose en plaques
EP2191271B1 (fr) 2007-07-27 2016-01-13 Universiteit Gent Cellules permissives et leurs utilisations
CA2696995C (fr) 2007-08-21 2017-11-21 Senomyx, Inc. Identification de recepteurs humains t2r sensibles aux composes amers qui provoquent le gout amer dans des compositions, et utilisation de ceux-ci dans des analyses d'identification de composes qui inhibent (bloquent) le gout amer dans des compositions et utilisation de celles-ci
GB0803076D0 (en) 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
PE20120021A1 (es) 2008-10-10 2012-02-10 Amgen Inc Mutantes fgf21
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
CN107188950B (zh) 2009-05-05 2021-09-28 安姆根有限公司 Fgf21突变体及其用途
MX2011011815A (es) 2009-05-05 2012-01-27 Amgen Inc Mutantes fgf21 y usos de los mismos.
CN102712688B (zh) 2009-09-23 2015-06-24 通益制药有限公司 重组人红细胞生成素(epo)的纯化方法、由此纯化的epo以及包含纯化的epo的药物组合物
EP2325194A1 (fr) 2009-11-24 2011-05-25 Glycotope GmbH Processus de purification de glycoprotéines
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US20120329092A1 (en) 2010-01-28 2012-12-27 Glycotope Gmbh Process for the purification of glycoproteins
CA2796055A1 (fr) 2010-04-15 2011-10-20 Amgen Inc. Proteines de liaison au recepteur de fgf humain et a ?-klotho
WO2011154453A1 (fr) 2010-06-09 2011-12-15 Genmab A/S Anticorps dirigés contre le cd38 humain
CN106084053B (zh) 2010-06-15 2020-01-17 根马布股份公司 针对组织因子的人抗体药物缀合物
RU2566267C2 (ru) 2010-09-14 2015-10-20 Ф. Хоффманн-Ля Рош Аг Способ очистки пегилированного эритропоэтина
WO2013003697A1 (fr) 2011-06-30 2013-01-03 Trustees Of Boston University Méthode de régulation de croissance tumorale, d'angiogenèse et de métastase à l'aide du récepteur 1 riche en proline et contenant une immunoglobuline (igpr-1)
WO2013009971A1 (fr) 2011-07-12 2013-01-17 E. I. Du Pont De Nemours And Company Procédé de détection et de criblage et matériaux utiles dans l'exécution de celui-ci
CA2844197A1 (fr) 2011-08-03 2013-02-07 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolina Healthcare System Traitement de fibrose au moyen de microarn-19b
UA115772C2 (uk) * 2011-12-16 2017-12-26 Таргітджин Байотекнолоджиз Лтд Композиція програмованого нуклеопротеїнового молекулярного комплексу і спосіб модифікування заданої послідовності нуклеїнової кислоти-мішені
CA2915948A1 (fr) 2013-08-20 2015-02-26 Lek Pharmaceuticals D.D. Milieux de culture cellulaire et procede pour reguler l'?-amidation et/ou le clivage d'acides amines c-terminaux de polypeptides
JP6841753B2 (ja) 2014-09-15 2021-03-10 ザ チルドレンズ メディカル センター コーポレーション ヒストンｈ３−リジントリメチル化を除去することによって体細胞核移入（ｓｃｎｔ）効率を増加させるための方法および組成物
CA3027143A1 (fr) 2016-07-15 2018-01-18 F. Hoffmann-La Roche Ag Procede de purification d'erythropoietine pegylee
HRP20220041T1 (hr) 2017-12-29 2022-04-15 F. Hoffmann - La Roche Ag Postupak za dobivanje pegiliranog proteinskog pripravka
KR102523239B1 (ko) 2017-12-29 2023-04-18 에프. 호프만-라 로슈 아게 페길화 단백질 조성물을 제공하기 위한 방법
HRP20220388T1 (hr) 2017-12-29 2022-05-27 F. Hoffmann - La Roche Ag Postupak za dobivanje pegiliranog proteinskog pripravka
WO2022159414A1 (fr) 2021-01-22 2022-07-28 University Of Rochester Érythropoïétine pour un dysfonctionnement gastrointestinal
WO2024091824A1 (fr) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Différenciation et reprogrammation de chondrocyte
WO2024129459A1 (fr) 2022-12-16 2024-06-20 University Of Rochester Réparation d'un dysfonctionnement de la barrière dans l'œsophage

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0225887B1 (fr) * 1985-04-08 1994-06-08 Amgen Inc. Procede et activeur hybride permettant de commander la transcription de genes exogenes
EP0273085A1 (fr) * 1986-12-29 1988-07-06 IntraCel Corporation Procédé pour faire entrer des acides nucléiques dans des cellules eucaryotes
ZA88319B (en) * 1987-02-06 1988-08-12 Lubrizol Enterprises, Inc. Ocs enhancer
GB8807683D0 (en) * 1988-03-31 1988-05-05 Ici Plc Regulation of gene expression
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
WO1991005052A1 (fr) * 1989-09-28 1991-04-18 Leningradsky Gosudarstvenny Universitet Procede d'obtention d'un polypeptide presentant une activite d'interleukine-2 humaine, secrete par des cellules de levure, saccharomyces cerevisiae
WO1991006666A1 (fr) * 1989-11-06 1991-05-16 Cell Genesys, Inc. Production de proteines par recombinaison homologue
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica

Also Published As

Publication number Publication date
HK1000786A1 (en) 2005-01-14
NO311896B1 (no) 2002-02-11
CA2071989A1 (fr) 1991-06-23
DE69034135D1 (de) 2004-05-27
JP3501286B2 (ja) 2004-03-02
LT3998B (en) 1996-06-25
RO109864B1 (ro) 1995-06-30
AR245776A1 (es) 1994-02-28
ES2151463T5 (es) 2012-10-29
LV10655B (en) 1995-08-20
EP0779362B2 (fr) 2012-06-13
HU217212B (hu) 1999-12-28
EP1484412A2 (fr) 2004-12-08
JP2004000233A (ja) 2004-01-08
UA42675C2 (uk) 2001-11-15
EP1375666A3 (fr) 2007-09-26
EP0779362B1 (fr) 2004-04-21
NO922436L (no) 1992-06-19
CA2071989C (fr) 1999-07-27
FI922863A0 (fi) 1992-06-18
HUT62657A (en) 1993-05-28
DE69034135T2 (de) 2004-08-26
AU7183691A (en) 1991-07-24
JP2004089200A (ja) 2004-03-25
DE69034135T3 (de) 2012-08-23
FI107391B (fi) 2001-07-31
IL116046A (en) 2007-03-08
RU2128227C1 (ru) 1999-03-27
IL164252A0 (en) 2005-12-18
ATE156189T1 (de) 1997-08-15
HU9202068D0 (en) 1992-10-28
HK1000547A1 (en) 1998-04-03
ATE264916T1 (de) 2004-05-15
IL116046A0 (en) 1996-01-31
DK0779362T3 (da) 2004-05-10
ES2151463T1 (es) 2001-01-01
FI922863A (fi) 1992-06-18
EP1375666A2 (fr) 2004-01-02
JP3740134B2 (ja) 2006-02-01
EP1482053A2 (fr) 2004-12-01
JPH05504682A (ja) 1993-07-22
ES2151463T3 (es) 2004-10-01
EP1482053A3 (fr) 2007-10-17
DK0779362T4 (da) 2012-07-30
DE69031172D1 (de) 1997-09-04
EP0505500B1 (fr) 1997-07-30
DK0505500T3 (da) 1997-08-25
BG96515A (bg) 1993-12-24
AU645294B2 (en) 1994-01-13
KR0176693B1 (ko) 1999-04-01
EP0779362A1 (fr) 1997-06-18
DE779362T1 (de) 2001-04-05
LTIP1595A (en) 1995-07-25
NO922436D0 (no) 1992-06-19
LV10655A (lv) 1995-04-20
WO1991009955A1 (fr) 1991-07-11
BG60624B1 (bg) 1995-10-31
BR9007937A (pt) 1992-11-17
GR3025057T3 (en) 1998-01-30
DE69031172T2 (de) 1998-03-12
IL96765A0 (en) 1991-09-16
ES2104690T3 (es) 1997-10-16
OA09594A (en) 1993-04-30
EP0505500A1 (fr) 1992-09-30
EP1484412A3 (fr) 2007-10-17

Similar Documents

Publication Publication Date Title
ZA9010392B (en) Method for the modification of the expression characteristics of an endogenous gene of given cell line or microorganism
GR3017307T3 (en) Method of gene mapping.
AU3866185A (en) Nucleic acid probe
AU7469787A (en) Process for the genetic modification of yeast
EP0411658A3 (en) Method for culturing cells
AU1902588A (en) An improved abrasive
AU573699B2 (en) Body support
AU591004B2 (en) An improved method
AU626147B2 (en) Fibrinolytic proteins
AU1561988A (en) Method of testing for corrosion
AU3841285A (en) Transesterification process
EP0415124A3 (en) An enzyme electrode
AU1836688A (en) An immunometric determination method
AU7281787A (en) Immortalized cells which produce tissue-specific products
AU1362088A (en) Method of assembly of an 02 assembly
AU2463988A (en) An improved method and composition
AU566318B2 (en) New solvates of beclome thasone 17,21-dipropionate
EG17786A (en) Vectors and method for gene expression
AU549234B2 (en) Device for the determination of microorganisms
GB8308903D0 (en) Enzyme liberation from bacterial cells
AU2409088A (en) Enzyme assay method
AU569689B2 (en) Pseudooligosaccharides with an alpha-glucosidase - inhibiting action
AU1885488A (en) Simplified microscope
AU8087591A (en) Mammalian adipogenic factors
AU579685B2 (en) Electrochemical process